Nasal Congestion Clinical Trial
Official title:
A Trial to Evaluate Efficacy and Safety of a Nasal Spray Combined With Standard of Care for Nasal Congestion in Infants and Toddlers With Common Cold in Comparison to Standard of Care Alone
Verified date | October 2023 |
Source | Church & Dwight Company, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study will evaluate the safety and efficacy of the study medical device plus standard of care versus standard of care in subjects between 3 and 48 months (inclusive) presenting symptoms of a common cold.
Status | Completed |
Enrollment | 220 |
Est. completion date | March 31, 2023 |
Est. primary completion date | March 31, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 3 Months to 48 Months |
Eligibility | Inclusion Criteria: 1. Male and female infants and toddlers. 2. Aged 3 - 48 months (inclusive) at enrolment (Day 0). 3. Parent/legal guardian answering "yes" to the question "Do you feel that your child has a cold?" at enrolment. 4. Subjects with symptoms started not later than 48 hours prior to enrolment (Day 0). 5. Subjects with nasal congestion (blocked / stuffy nose) rated as at least score of 2 (moderately bothersome) on a 0 to 3-point scale, based on morning evaluation (within an hour of child awakening). 6. Subjects showing at least one of the following additional signs of cold symptoms: runny nose, nasal crust (dry mucus), thick mucus, sneezing and cough. 7. Parent/legal guardian of the subject has given freely and expressly her/his informed consent. 8. Parent/legal guardian is cooperative and aware of the necessity and duration of the controls so that perfect adhesion to the protocol established by the clinical trial center could be expected. Exclusion Criteria: 1. Subjects presenting an oral temperature greater than 38°C at enrolment (Day 0). 2. Subjects presenting any secondary infection (such as bronchitis, otitis, tracheitis, pneumonia, etc.) at enrolment (Day 0). 3. Subjects with positive results on a streptococcal antigen screening test (rapid antigen detection test or RADT) at inclusion. 4. Subjects with a history of allergic rhinitis 5. Subjects presenting any congenital or chronic disease that in the opinion of the Investigator would adversely affect the results of the study (e.g. asthma, pneumonia, laryngotracheobronchitis, sinusitis, etc). 6. Subjects presenting any kind of immunodeficiency. 7. Subjects presenting any hypersensitivity or allergy or intolerance to any component of the study products or of the rescue medication (paracetamol) 8. Subjects with a positive medical history to any significant illness within the 2 weeks prior to the enrolment (Day 0). 9. Subjects presenting any active systemic infection or medical condition that may require treatment or therapeutic intervention during the study. 10. Subjects currently participating or having participated in another clinical trial during the last 30 days prior to enrolment (Day 0). 11. Subjects using saline nose drops or nasal sprays or pumps other than the study products, antibiotics, antivirals, intranasal medicines, decongestants, antihistamines, echinacea, combination cold formulas, supplements containing = 10 mg zinc that would influence symptoms scores at enrolment (Day 0) within 12 hours prior the day of screening 12. Subject who was abroad in a country with a higher incidence rate of Covid-19 than Poland, within 14 days before the beginning of the study. 13. Subject who have had contact with any person infected with COVID-19 within 10 days before the beginning of the study. 14. Subject who are currently home quarantined, as recommended by the Sanitary Inspection. |
Country | Name | City | State |
---|---|---|---|
Poland | PRIVATE PRACTICE ul. Osiedle Sierakowskich 5 | Sztum |
Lead Sponsor | Collaborator |
---|---|
Church & Dwight Company, Inc. |
Poland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Onset of relief | Assessment of onset of relief (immediate relief) after the entire product application is completed (1 or 2 sprays) at Day 0 (baseline) and daily from Day 1 to Day 3 of the study; within investigational device group.
the study. |
assessed at 5, 15, and 30 minutes post first application of device every morning from Day 0 to 3 | |
Other | Concomitant medications | Assessment of use of concomitant medications (frequency, excluding paracetamol) will be done from the beginning to the end of the study; comparisons between groups. | Through study completion, an average of 10 days. | |
Other | Frequency of paracetamol administration. | Assessment of use of paracetamol (frequency) will be done from the beginning to the end of the study; comparisons between groups. | Through study completion, an average of 10 days. | |
Other | Quality of sleep. | Assessment of quality of sleep will be evaluated by means of a questionnaire ("Quality of Sleep Questionnaire"), on a 0 to 3-point scale, with higher score indicating a worse outcome, with 0=not at all, 1=slightly, 2=moderately and 3=severely, to be completed from Day 0 (baseline) and daily from the beginning to the end of the study; comparisons between groups. | Through study completion, an average of 10 days. | |
Other | Global assessment on common cold status. | Global assessment on common cold status will be evaluated by means of the "Global Assessment on Common Cold Status Questionnaire", on a 0 to 3-point scale, with higher score indicating a better outcome, with 0=no relief at all, 1=slight relief, 2=moderate relief and 3=complete relief, to be completed from the beginning to the end of the study; comparisons between groups. | Through study completion, an average of 10 days. | |
Primary | Change of nasal congestion | Assess reduction of nasal congestion, evaluated by means of a specific questionnaire ("Cold Symptom Severity Questionnaire") on a 0 to 3-point scale, with higher score indicating a worse outcome, with 0 =not at all, 1=mild, 2=moderate and 3=severe to be completed at Day 0 (baseline) and daily from the beginning to the end of the study; comparisons between groups. | Through study completion, an average of 10 days. | |
Secondary | Change of other cold symptoms | Assess change of other cold symptoms, evaluated by means of a specific questionnaire ("Cold Symptom Severity Questionnaire"),on a 0 to 3-point scale, with higher score indicating a worse outcome, with 0=not at all, 1=mild, 2=moderate and 3=severe, to be completed at Day 0 (baseline) and daily from the beginning to the end of the study; comparisons between groups.
Other cold symptoms: Stuffy nose, Nasal crust, Runny nose, Thick mucus, Sneezing, Cough |
Through study completion, an average of 10 days. | |
Secondary | Occurrence of secondary infections | Assessment of occurrence of secondary infections (number) daily, from the beginning to the end of the study; comparison between groups. Secondary infections will be confirmed by the Investigator. | Through study completion, an average of 10 days. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00665977 -
Effect of Heated Humidity With Thermosmartâ„¢ Compared to an Intranasal Steroid in Improving Compliance and Nasal Symptoms in Patients Using Continuous Positive Airway Pressure
|
Phase 3 | |
Completed |
NCT05843071 -
PMCF Study to Evaluate Performance and Safety of "NASAL SPRAYS " Used to Relieve Nasal Congestion and Dryness
|
N/A | |
Completed |
NCT00957996 -
Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza
|
Phase 3 | |
Completed |
NCT00829634 -
Steady State Kinetics of l-Methamphetamine and Validation of Sensitivity of Dose Estimation
|
N/A | |
Completed |
NCT00662337 -
Bioequivalence Between Two Oral Formulations of Diphenhydramine Hydrochloride
|
Phase 1 | |
Completed |
NCT05247333 -
Implementation of a Minor Ailment Service in Community Pharmacy Practice
|
N/A | |
Recruiting |
NCT05244148 -
Two Seawater-based Formulations for Relief of Nasal Congestion in Paediatric Subjects
|
N/A | |
Completed |
NCT05159271 -
Efficacy and Safety of Azeol Nasal Spray Versus Placebo in the Treatment of Early Symptoms of Common Cold in Adults
|
N/A | |
Completed |
NCT02113449 -
Market Potential of Carbon Dioxide Nasal Spray
|
Phase 2 | |
Terminated |
NCT00958776 -
A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza
|
Phase 3 | |
Completed |
NCT00648973 -
To Determine if Diphenhydramine Works for Nasal Congestion at Two Different Doses
|
Phase 4 | |
Completed |
NCT03399721 -
Investigation of Kinetic Oscillation Stimulation by the Chordate System S101 in the Treatment of Non Allergic Rhinitis
|
N/A | |
Completed |
NCT01354418 -
Bioequivalence of Single Dose Phenylephrine Extended Release Tablets and Phenylephrine HCl Immediate Release Tablets Dosed Every Four Hours (P08340)(COMPLETED)
|
Phase 1 | |
Completed |
NCT04797936 -
BNO 1030 Extract (Imupret) in the Treatment of Mild Forms of COVID-19
|
Phase 4 | |
Completed |
NCT03906968 -
The Safety and Efficacy of a SinuSonic Intervention
|
N/A | |
Completed |
NCT02100605 -
Study on Hypertonic Saline Nasal Spray
|
N/A | |
Recruiting |
NCT06323304 -
Efficacy and Safety of Auricular Acupressure in Treating Allergic Rhinitis
|
N/A | |
Withdrawn |
NCT04790487 -
Chlorpheniramine Maleate Nasal Spray for Chronic Rhinitis
|
Phase 2/Phase 3 | |
Completed |
NCT01448057 -
Evaluation of Efficacy and Safety of Tablets of Paracetamol, Dimethindene Maleate and Phenylephrine Hydrochloride in Reducing Symptoms of Common Cold and Flu
|
Phase 3 | |
Completed |
NCT01129765 -
Home Usability of a Nasal Lavage System in Children
|
N/A |